As of December 31, 2023, Pyxis Oncology had cash and cash equivalents, including restricted cash, and short-term investments of $120.8 million. Following the end of fiscal year 2023, we raised gross proceeds of $10.8 million via ATM offering and completed $50 million of private placement. Pyxis Oncology expects to have the resources to fund operations into 2nd half of 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PYXS:
- Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
- PYXS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Pyxis Oncology Bolsters Board with New Independent Director
- Pyxis Oncology appoints Santhosh Palani to board of directors
- Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
